Jonas Wallvik

1.3k total citations
32 papers, 871 citations indexed

About

Jonas Wallvik is a scholar working on Hematology, Genetics and Management of Technology and Innovation. According to data from OpenAlex, Jonas Wallvik has authored 32 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 15 papers in Genetics and 8 papers in Management of Technology and Innovation. Recurrent topics in Jonas Wallvik's work include Acute Myeloid Leukemia Research (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Blood transfusion and management (8 papers). Jonas Wallvik is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Blood transfusion and management (8 papers). Jonas Wallvik collaborates with scholars based in Sweden, Denmark and Norway. Jonas Wallvik's co-authors include Claes F. Högman, Lars Eriksson, Leif Stenke, Olof Åkerblom, Kenneth Hedlund, Robert Hast, Per Bernell, A. Lindgren, Lennart Stigendal and Martin Fahlén and has published in prestigious journals such as Blood, Stroke and Clinical Cancer Research.

In The Last Decade

Jonas Wallvik

32 papers receiving 827 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonas Wallvik Sweden 17 445 215 187 139 130 32 871
E. Shannon Cooper United States 10 144 0.3× 76 0.4× 253 1.4× 99 0.7× 31 0.2× 24 737
P. H. Pinkerton Canada 18 437 1.0× 327 1.5× 113 0.6× 25 0.2× 38 0.3× 71 1.1k
M. Blombäck Sweden 18 552 1.2× 102 0.5× 44 0.2× 185 1.3× 35 0.3× 46 1.0k
Cyrus C. Hsia Canada 11 258 0.6× 118 0.5× 75 0.4× 42 0.3× 22 0.2× 83 541
Hajna Losonczy Hungary 9 258 0.6× 64 0.3× 47 0.3× 324 2.3× 18 0.1× 50 686
Türker Çetin Türkiye 13 171 0.4× 98 0.5× 19 0.1× 64 0.5× 19 0.1× 30 603
Harold A. Wurzel United States 14 181 0.4× 78 0.4× 54 0.3× 67 0.5× 15 0.1× 42 579
G Patrassi Italy 18 460 1.0× 104 0.5× 32 0.2× 113 0.8× 18 0.1× 68 953
Sean Rudnick United States 14 118 0.3× 36 0.2× 98 0.5× 24 0.2× 18 0.1× 26 592
Kaan Kavaklı Türkiye 19 755 1.7× 269 1.3× 24 0.1× 35 0.3× 11 0.1× 81 1.2k

Countries citing papers authored by Jonas Wallvik

Since Specialization
Citations

This map shows the geographic impact of Jonas Wallvik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonas Wallvik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonas Wallvik more than expected).

Fields of papers citing papers by Jonas Wallvik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonas Wallvik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonas Wallvik. The network helps show where Jonas Wallvik may publish in the future.

Co-authorship network of co-authors of Jonas Wallvik

This figure shows the co-authorship network connecting the top 25 collaborators of Jonas Wallvik. A scholar is included among the top collaborators of Jonas Wallvik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonas Wallvik. Jonas Wallvik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Själander, Anders, et al.. (2023). Direct oral anticoagulants: patient reported adherence and minor bleedings. Journal of Thrombosis and Thrombolysis. 56(1). 55–64. 2 indexed citations
2.
Malyukova, Alena, Dorina Ujvári, Márton Keszei, et al.. (2021). Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells. Cell Death and Disease. 12(10). 875–875. 10 indexed citations
3.
Mulligan, Stephen P., Karin Karlsson, Viggo Jønsson, et al.. (2014). Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Leukemia & lymphoma. 55(12). 2769–2777. 13 indexed citations
4.
Höglund, Martin, Fredrik Sandin, Magnus Björkholm, et al.. (2014). Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era. Blood. 124(21). 154–154. 3 indexed citations
5.
Nilsson‐Ehle, Herman, Gunnar Birgegård, Jan Samuelsson, et al.. (2011). Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. European Journal Of Haematology. 87(3). 244–252. 49 indexed citations
6.
Wallvik, Jonas, et al.. (2007). Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scandinavian Journal of Primary Health Care. 25(2). 123–128. 42 indexed citations
7.
Björkander, Janne, J Nikoskelainen, Heinz Leibl, et al.. (2006). Prospective open‐label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo‐ or agammaglobulinemia. Vox Sanguinis. 90(4). 286–293. 40 indexed citations
8.
9.
Wallvik, Jonas, Leif Stenke, Per Bernell, et al.. (2002). Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. European Journal Of Haematology. 68(3). 180–186. 29 indexed citations
10.
Hårdemark, Hans‐Göran, A. Lindgren, Bo Norrving, et al.. (2001). Management and Prognostic Features of Intracerebral Hemorrhage During Anticoagulant Therapy: A Swedish Multicenter Study. Stroke. 32(11). 2567–2574. 159 indexed citations
11.
Hast, Robert, et al.. (2001). Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leukemia Research. 25(1). 13–18. 17 indexed citations
12.
13.
Högman, Claes F., Lars Eriksson, Jonas Wallvik, & Jean‐Marc Payrat. (1997). Clinical and Laboratory Experience with Erythrocyte and Platelet Preparations from a 0.5CPD Erythro‐Sol Opti System. Vox Sanguinis. 73(4). 212–219. 37 indexed citations
14.
Bernell, Per, et al.. (1996). A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes. Leukemia Research. 20(8). 693–699. 16 indexed citations
15.
Stenke, Leif, Jonas Wallvik, Fredrik Celsing, & Robert Hast. (1993). Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.. PubMed. 7(9). 1324–7. 41 indexed citations
16.
Wallvik, Jonas, et al.. (1993). Limited metabolic effect of mononuclear cells in platelet storage. Thrombosis Research. 70(3). 255–264. 1 indexed citations
17.
Wallvik, Jonas, et al.. (1992). Proteolytic activity during storage of platelets in plasma. Transfusion Medicine. 2(2). 135–142. 13 indexed citations
18.
Wallvik, Jonas & Olof Åkerblom. (1990). The Platelet Storage Capability of Different Plastic Containers. Vox Sanguinis. 58(1). 40–44. 19 indexed citations
19.
Wallvik, Jonas, Leif Stenke, & Olof Åkerblom. (1990). The effect of different agitation modes on platelet metabolism, thromboxane formation, and alpha‐granular release during platelet storage. Transfusion. 30(7). 639–643. 28 indexed citations
20.
Högman, Claes F., Lars Eriksson, Kenneth Hedlund, & Jonas Wallvik. (1988). The Bottom and Top System: A New Technique for Blood Component Preparation and Storage. Vox Sanguinis. 55(4). 211–217. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Shannon Cooper Breakdown of academic impact, for papers by P. H. Pinkerton Breakdown of academic impact, for papers by M. Blombäck Breakdown of academic impact, for papers by Cyrus C. Hsia Breakdown of academic impact, for papers by Hajna Losonczy Breakdown of academic impact, for papers by Türker Çetin Breakdown of academic impact, for papers by Harold A. Wurzel Breakdown of academic impact, for papers by G Patrassi Breakdown of academic impact, for papers by Sean Rudnick Breakdown of academic impact, for papers by Kaan Kavaklı
Rankless by CCL
2026